Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5801154A · kind A · utility
820Cited by
4References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 8, 1997 |
| Grant date | Sep 1, 1998 |
| Priority date | — |
| Expiry date | Apr 8, 2017 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3517
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compositions and methods are provided for the treatment and diagnosis of diseases or conditions amenable to treatment through modulation of the synthesis or metabolism of multidrug resistance-associated protein (MRP). In accordance with referred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding MRP. In a preferred embodiment, the oligonucleotide has at least one 2'-methoxyethoxy modification. Methods of preventing the development of multidrug resistance and of improving the efficacy of chemotherapy are also disclosed.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.